← All Bluejay Diagnostics, INC filings

Bluejay Diagnostics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
BJDX
Bluejay Diagnostics, INC
10-K: Bluejay Diagnostics Faces Going Concern Amidst Funding Crisis
Bluejay Diagnostics reported significant losses, a going concern warning, and critical funding needs to advance its Symphony platform and FDA submission.
NASDAQ
BJDX
Bluejay Diagnostics, INC
10-K/A: Bluejay Diagnostics Amends 10-K to Include Omitted Information and Board Changes
Bluejay Diagnostics files an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, corporate governance, and recent board composition changes.
NASDAQ
BJDX
Bluejay Diagnostics, INC
10-K: Bluejay Diagnostics Reports Significant Losses, Outlines Strategy for FDA Approval in 2028
Bluejay Diagnostics faces substantial financial challenges and is pursuing FDA approval for its Symphony platform by Q3 2028, contingent on securing significant funding and overcoming technical hurdles.
NASDAQ
BJDX
Bluejay Diagnostics, INC
10-K: Bluejay Diagnostics Details Capital Structure and Risk Factors in 10-K Filing
Bluejay Diagnostics' 10-K filing outlines its capital structure, ongoing financial challenges, and risks associated with its business and technology.